Ovarian microenvironment, angiogenic & paracrine trophic support
Stem cell therapy for premature ovarian insufficiency in Istanbul, Turkey
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your hormone profile, ultrasound findings, and reproductive history to design an individualized Wharton's jelly MSC and exosome protocol.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Premature ovarian insufficiency (POI — also widely searched as premature ovarian failure) occurs when the delicate ovarian cortex and stroma experience premature inflammatory, oxidative, and microvascular decline before age 40. Inside the ovary, developing and dormant primordial follicles depend on continuous metabolic nourishment from surrounding granulosa cells and a rich capillary network; when stromal fibrosis, autoimmune inflammation, or mitochondrial oxidative stress disrupts this niche, granulosa cells undergo apoptosis, estrogen production drops, FSH rises, and women experience irregular or absent cycles, vasomotor symptoms, and emotional strain.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated in premature ovarian insufficiency because many women with POI retain residual dormant follicles that are starved of healthy paracrine and vascular support. Administered within an individualized regenerative protocol, WJ-MSCs and their nanoscale exosomes release potent pro-angiogenic and trophic growth factors — including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), and epidermal growth factor (EGF) — alongside anti-apoptotic and anti-fibrotic microRNAs (such as miR-21 and miR-144). These biological signals help calm autoimmune oophoritis by shifting M1 macrophages to reparative M2 states and expanding regulatory T-cells, attenuate TGF-beta-driven stromal collagen fibrosis, stimulate cortical capillary angiogenesis, and protect granulosa cells from oxidative apoptosis so the ovarian microenvironment is better nourished.
At our Istanbul clinic, Uzm. Dr. Cihan Bolat and our medical team carefully review your menstrual history, hormone panel (FSH, LH, estradiol, AMH), and pelvic ultrasound findings to design a personalized WJ-MSC and exosome protocol coordinated alongside your home gynecologist or fertility specialist. Our goal is to support ovarian stromal vitality, healthier endocrine balance, and overall systemic wellbeing.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
Because residual dormant follicles can persist in premature ovarian insufficiency, regenerative medicine investigates how paracrine growth factors, angiogenesis, and anti-inflammatory signaling can help repair and nourish the ovarian stromal niche.
What our protocol aims to support
- Nourishing the ovarian stromal microenvironment: Delivering paracrine growth factors and exosomal microRNAs aimed at reducing stromal fibrosis and supporting healthier granulosa-cell metabolic resilience.
- Supporting microvascular & angiogenic signaling: Providing pro-angiogenic biological signals (such as VEGF and HGF) to support capillary perfusion and nutrient delivery within reproductive tissues.
- Calming autoimmune & oxidative ovarian stress: Using systemic WJ-MSC and exosome immunomodulation to help balance inflammatory cytokines and support overall endocrine and cellular vitality.
- Coordinated alongside your gynecologist or fertility specialist: Your Istanbul regenerative protocol is designed to complement the hormone replacement or reproductive planning managed by your specialist at home.
- 01
Ovarian stromal inflammation & cortical fibrosis
In premature ovarian insufficiency, autoimmune lymphocyte infiltration, prior medical treatments, or accelerated tissue aging trigger chronic inflammatory signaling within the ovarian cortex. Overactive TGF-beta pathways stimulate stromal fibroblasts to deposit dense collagen fibers, stiffening the ovarian cortex and mechanically and biochemically restricting dormant primordial follicles. Wharton's jelly MSCs and exosomes release hepatocyte growth factor (HGF), anti-fibrotic microRNAs, and immunomodulatory IL-10 that calm stromal inflammation and downregulate collagen deposition. Softening and remodeling the fibrotic ovarian stroma helps restore a more permissive biomechanical environment for follicular signaling.
- 02
Granulosa cell oxidative stress & premature apoptosis
Granulosa cells form the essential life-support wrapper around every oocyte, supplying pyruvate, amino acids, estradiol (via aromatase), and paracrine survival signals. When mitochondrial dysfunction and reactive oxygen species (ROS) accumulate inside granulosa cells, they undergo Caspase-3-mediated apoptosis, starving the enclosed follicle and leading to follicular atresia. WJ-MSC-derived exosomes transfer protective microRNAs (including miR-21 and miR-144) and IGF-1 directly into granulosa cells, activating the pro-survival PI3K/Akt pathway and boosting antioxidant defenses. Protecting granulosa cells from oxidative death helps preserve steroidogenic (estradiol) and follicular support capacity.
- 03
Reduced ovarian cortical microvascular perfusion
Maturing follicles require a dense, responsive perifollicular capillary bed to deliver oxygen, cholesterol substrates for hormone synthesis, and pituitary gonadotropins (FSH and LH). In POI, microvascular rarefaction and endothelial injury leave the ovarian cortex hypoxic and nutrient-depleted. WJ-MSCs and their exosomes secrete vascular endothelial growth factor (VEGF), angiopoietins, and HGF, which stimulate endothelial repair and neo-angiogenesis throughout the ovarian stroma. Enhancing local microvascular blood flow helps restore oxygen and hormone delivery to residual follicular structures.
- 04
Impaired intra-ovarian paracrine trophic signaling
Healthy follicular activation and growth rely on delicate local cross-talk mediated by insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), GDF-9, and BMP-15 between stromal cells, granulosa cells, and the oocyte. Chronic inflammation and cellular senescence silence these local growth-factor networks, leaving residual follicles unresponsive even when pituitary FSH is high. By supplying exogenous IGF-1, HGF, VEGF, and regulatory exosomal vesicles, our biological protocol helps replenish the ovarian trophic milieu and support healthier intercellular communication.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Nourishing the Residual Ovarian Niche
Even when menstrual cycles pause and serum FSH rises in premature ovarian insufficiency (POI), histological studies show that many ovaries still contain dormant primordial or pre-antral follicles trapped within a stiffened, poorly vascularized cortex. These residual follicles fail to mature when surrounding granulosa cells suffer mitochondrial oxidative stress and the ovarian stroma becomes fibrotic and inflamed. Regenerative medicine is investigated not to manufacture brand-new germ cells from scratch, but to repair and re-vascularize the stromal and granulosa-cell microenvironment that supports surviving follicles. Restoring this local biochemical niche is the central biological rationale of therapy.
How WJ-MSCs & Exosomes Support Granulosa & Stromal Cells
Wharton's jelly-derived MSCs (WJ-MSCs) secrete a rich cocktail of ovarian-trophic growth factors — including IGF-1, VEGF, HGF, and bFGF — while calming autoimmune and inflammatory cytokine cascades (TNF-alpha, IFN-gamma) via regulatory T-cell and M2 macrophage polarization. In parallel, nanoscale WJ-MSC exosomes transfer anti-apoptotic microRNAs (such as miR-21, miR-144-5p, and miR-29) and antioxidant proteins directly into stressed granulosa and theca cells. This vesicular cargo inhibits granulosa-cell apoptosis (via PI3K/Akt and Bcl-2 pathways), reduces reactive oxygen species, and downregulates TGF-beta stromal fibrosis to soften the ovarian cortex and improve capillary blood flow.
Endocrine-Guided Protocol & Specialist Coordination
Every woman's ovarian reserve timeline, hormone trajectory, and personal health or family-building goals are unique. Before recommending treatment in Istanbul, Uzm. Dr. Cihan Bolat and our medical team evaluate your repeat FSH, LH, estradiol (E2), AMH, thyroid and autoimmune panels, and transvaginal ultrasound antral follicle count (AFC). We then customize your GMP-certified WJ-MSC and exosome dosage and administration schedule to work harmoniously alongside the care of your home gynecologist or reproductive endocrinologist, followed by structured 1, 3, and 6-month hormone and ultrasound monitoring.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intravenous WJ-MSC & Exosome Administration
Intravenous administration delivers GMP-certified Wharton's jelly mesenchymal stem cells and concentrated nanoscale exosomes into the systemic circulation, where they home toward inflamed and hypoxic tissues and release a sustained wave of ovarian-supportive factors. Through systemic immunomodulation, WJ-MSCs calm autoimmune T-cell and macrophage reactivity (shifting M1 macrophages toward reparative M2 states), while circulating exosomes and growth factors (VEGF, HGF, IGF-1) reach the ovarian vasculature to support endothelial repair, reduce granulosa-cell oxidative apoptosis, and soften stromal fibrosis. This route also provides systemic support for vasomotor comfort, bone-remodeling balance, and cellular vitality. We note transparently that while combined cellular and exosomal signaling is biologically complementary, whether combined MSC + exosome therapy outperforms single-modality treatment remains under clinical study.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Individualized Reproductive & Endocrine Evaluation
Every patient inquiring about premature ovarian insufficiency receives a comprehensive, individualized endocrine and anatomical review by Uzm. Dr. Cihan Bolat and our medical team before travel. We evaluate your age, menstrual timeline, repeat serum FSH, LH, estradiol (E2), and AMH levels, thyroid and autoimmune antibodies, and pelvic/transvaginal ultrasound reports (ovarian volume and antral follicle count). This detailed assessment allows us to tailor the exact WJ-MSC cell dosage, exosome concentration, and treatment schedule to your biological profile while setting clear, realistic clinical expectations.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Coordinated Follow-Up Alongside Your Gynecologist or Fertility Specialist
Our regenerative program in Istanbul is designed to integrate seamlessly with the ongoing care provided by your home gynecologist or reproductive endocrinologist. We never ask you to delay time-sensitive fertility preservation or assisted-reproduction counseling, and we coordinate any temporary hormone replacement washout windows for accurate baseline lab testing directly with your specialist. Following your Istanbul visit, we provide full laboratory and treatment documentation and conduct structured 1, 3, and 6-month follow-up reviews to track your hormone panel (FSH, E2, AMH), ultrasound findings, and menstrual cycle patterns.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
Endocrine Balance (FSH, Estradiol & AMH Trends)
By protecting granulosa cells from oxidative apoptosis and supporting steroidogenic signaling with IGF-1 and HGF, our protocol aims to support healthier estradiol (E2) and FSH hormone trajectories over 1, 3, and 6 months.
- 02
Ovarian Stromal Perfusion & Antral Follicle Activity
Delivering pro-angiogenic VEGF and anti-fibrotic exosomes to the ovarian cortex aims to support ovarian microvascular blood flow, stromal suppleness, and antral follicle count (AFC) observations tracked on ultrasound with your home gynecologist.
- 03
Menstrual Cycle Rhythm & Vasomotor Comfort
Supporting endogenous ovarian hormone signaling and calming systemic inflammation helps ease hot flashes, night sweats, sleep disruption, and cycle irregularity.
- 04
Systemic Cellular Vitality & Emotional Wellbeing
Restoring immune equilibrium and supporting mitochondrial energy across endocrine tissues helps improve daily physical stamina, mood resilience, and long-term wellness alongside your specialist care.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your hormone profile, ultrasound findings, and reproductive history to design an individualized Wharton's jelly MSC and exosome protocol.
Medical history & reports we request
- Age, menstrual cycle history, and confirmed POI / diminished ovarian reserve timeline
- Recent hormone panel including FSH, LH, estradiol (E2), AMH, prolactin, and TSH
- Recent pelvic or transvaginal ultrasound report noting ovarian volume and antral follicles
- Any genetic (karyotype, FMR1) or autoimmune screening results if previously performed
- Current hormone replacement therapy (HRT), supplements, and reproductive goals
Clinical suitability & protocol checks
- Patients continue their gynecologist-prescribed hormone replacement or endocrine care unless their home specialist recommends a specific laboratory washout window.
- Time-sensitive fertility preservation or assisted reproduction discussions with your home reproductive endocrinologist should continue in parallel without delay.
- Your Istanbul visit is arranged with private airport transfers, multilingual coordination, and structured 1, 3, and 6-month endocrine follow-up.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- Patients continue their gynecologist-prescribed hormone replacement or endocrine care unless their home specialist recommends a specific laboratory washout window.
- Time-sensitive fertility preservation or assisted reproduction discussions with your home reproductive endocrinologist should continue in parallel without delay.
- Your Istanbul visit is arranged with private airport transfers, multilingual coordination, and structured 1, 3, and 6-month endocrine follow-up.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 Mesenchymal stromal cell pilot clinical study in premature ovarian insufficiency
Open study- Product
- Umbilical cord and Wharton's jelly mesenchymal stromal cells
- Route
- Clinical regenerative administration protocols
- Study design
- Early-phase human clinical study evaluating safety and ovarian biomarkers
- Finding
- Early clinical research explores the safety of MSC protocols and tracks endocrine markers (FSH, estradiol) and follicular activity in women with POI.
- Limitation
- Clinical studies remain early-phase with small sample sizes, and regenerative protocols support the ovarian microenvironment rather than guaranteeing oocyte generation or pregnancy.
Scientific references
Clinical studies and scientific references
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.